Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.59 |
| ▸ | ESR1 | P03372 | 3/20 | 0.54 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.54 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.53 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.52 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | HTR1A | P08908 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | HTR3A | P46098 | 1/20 | 0.52 |
| ▸ | BACE1 | P56817 | 1/20 | 0.52 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | ACHE | P22303 | 3/20 | 0.50 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.50 |
| ▸ | TACR2 | P21452 | 2/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.50 |
| ▸ | SGMS1 | Q86VZ5 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4938894 | 0.94 | ACHE (0.57) | CA2ESR1ESR2ADRA2ASLC6A2 | |
| SCHEMBL5724132 | 0.92 | ACHE (0.60) | CA2ESR1ESR2ADRA2ASLC6A2 | |
| SCHEMBL31390626 | 0.92 | ACHE (0.60) | CA2ESR1ESR2ADRA2ASLC6A2 | |
| SCHEMBL154384 | 0.89 | CA2 (0.61) | CA2ESR1ESR2TRPV1ADRA2A | |
| SCHEMBL7753254 | 0.84 | ESR1 (0.56) | CA2ESR1ESR2TRPV1ADRA2A | |
| Hydroxyphenyl Propionic Acid SCHEMBL27946436 | 0.84 | FFAR1 (0.55) | CA2ESR1ESR2TRPV1DPP4 | |
| SCHEMBL20399733 | 0.83 | HDAC2 (0.62) | CA2ESR1ESR2ADRA2ASLC6A2 | |
| SCHEMBL284671 | 0.83 | SMN1; SMN2 (0.69) | CA2ESR1ESR2TRPV1ALDH1A1 | |
| SCHEMBL547175 | 0.83 | GFER (0.54) | ALDH1A1SLC6A3TDP1CYP3A4HSD17B10 | |
| SCHEMBL27676578 | 0.83 | TPSAB1 (0.48) | SLC6A3TDP1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6028224-A | Fluoxetine process from benzoylpropionic acid | SEPRACOR INC. (US) | 2000-02-22 | — | — | US | claimed |
| WO-1999067196-A1 | FLUOXETINE PROCESS FROM BENZOYLPROPIONIC ACID | SEPRACOR INC. (US) | 1999-12-29 | — | — | WO | claimed |
| US-5936124-A | Fluoxetine process from benzoylpropionic acid | SEPACOR INC. (US) | 1999-08-10 | — | — | US | claimed |
| CN-108250191-B | 3, 5-disubstituted 2-amino-pyrazine compound and preparation process and application thereof | 兰州大学 | 2020-10-20 | — | — | CN | disclosed |
| US-20200270655-A1 | CYSTEINE POLYSULFIDATION AND MITOCHONDRIAL BIOENERGETICS REGULATED BY CYSTEINYL-tRNA SYNTHETASE | AKAIKE, TAKAAKI (JP) | 2020-08-27 | — | — | US | disclosed |
| US-20130012692-A1 | SODIUM CHANNEL BLOCKERS | PARION SCIENCES, INC. (US) | 2013-01-10 | — | — | US | disclosed |
| US-8227474-B2 | Sodium channel blockers | PARION SCIENCES, INC. (US) | 2012-07-24 | — | — | US | disclosed |
| WO-2011006935-A2 | TETRAZOLE DERIVATIVES | MERCK SERONO S.A. (CH) | 2011-01-20 | — | — | WO | disclosed |
| US-20100144661-A1 | SODIUM CHANNEL BLOCKERS | PARION SCIENCES, INC. (US) | 2010-06-10 | — | — | US | disclosed |
| US-20080207822-A1 | COMPOSITION AND ASSOCIATED METHOD | GENERAL ELECTRIC COMPANY (US) | 2008-08-28 | — | — | US | disclosed |
| EP-1335908-B1 | PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONISTS | LILLY CO ELI (US) | 2008-02-13 | — | — | EP | disclosed |
| US-20030105132-A1 | N-phenpropylcuclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase | PFIZER INC. | 2003-06-05 | — | — | US | disclosed |
| US-20030096019-A1 | Methods of using norfluoxetine | SEPRACOR INC. | 2003-05-22 | — | — | US | disclosed |
| US-6316467-B1 | Elevation of HDL cholesterol by 4-[(Aminothioxomethyl)-hydrazono]-N-(substituted)-4-arylbutanamides | AMERICAN HOME PRODUCTS CORPORATION | 2001-11-13 | — | — | US | disclosed |
| EP-1070084-A4 | PIPERAZINES AS INHIBITORS OF FRUCTOSE-1,6-BISPHOSPHATASE (FBPase) | ONTOGEN CORP (US) | 2001-09-12 | — | — | EP | disclosed |
| EP-1070084-A1 | PIPERAZINES AS INHIBITORS OF FRUCTOSE-1,6-BISPHOSPHATASE (FBPase) | Ontogen Corporation (US) | 2001-01-24 | — | — | EP | disclosed |
| US-6028224-A | Fluoxetine process from benzoylpropionic acid | SEPRACOR INC. (US) | 2000-02-22 | — | — | US | disclosed |
| WO-1999067196-A1 | FLUOXETINE PROCESS FROM BENZOYLPROPIONIC ACID | SEPRACOR INC. (US) | 1999-12-29 | — | — | WO | disclosed |
| WO-1999047549-A1 | PIPERAZINES AS INHIBITORS OF FRUCTOSE-1,6-BISPHOSPHATASE (FBPase) | ONTOGEN CORPORATION (US) | 1999-09-23 | — | — | WO | disclosed |
| US-5936124-A | Fluoxetine process from benzoylpropionic acid | SEPACOR INC. (US) | 1999-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030096019-A1 | Methods of using norfluoxetine | NGF, TPH2, ALOX5 | CA2 2947/4885ESR1 3066/4885ESR2 2408/4885 |
| US-20030105132-A1 | N-phenpropylcuclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase | PREP, ENGASE, ENPEP | CA2 279/4885ESR1 778/4885ESR2 177/4885 |
| US-20100144661-A1 | SODIUM CHANNEL BLOCKERS | HCN4, SCN5A, SCN2B | CA2 145/4885ESR1 4647/4885ESR2 4050/4885 |
| US-20130012692-A1 | SODIUM CHANNEL BLOCKERS | HCN4, SCN2B, SCN5A | CA2 162/4885ESR1 4537/4885ESR2 4219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.